RecruitingNCT07182214
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers
Sponsor
Pharus Taiwan, Inc.
Enrollment
1,340 participants
Start Date
May 5, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Female or male participants at least 18 years of age
- Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study.
- Participants in the test group should be treatment naïve.
- Ability to complete a questionnaire, comprehend and comply with the requirements of the study
- Written informed consent, and authorization to use and disclose health information
Exclusion Criteria7
- Has any history of cancer diagnosis
- Has received a blood transfusion (except for autologous blood transfusion) within the first two months prior to participating the trial
- Is participating in a clinical trial (the non-intervention trial will be accepted)
- Has taken gene therapy within one year prior to participating the trial
- Has any vaccinations within 3 months prior to blood sample collection
- Is currently pregnant
- Has any severe acute or uncontrolled chronic lung disease such as pneumonia, lung abscess, acute exacerbation of COPD or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study
Interventions
OTHERCollect blood sample
Collect venous blood sample from subjects prior fasting, any operation or treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07182214
Related Trials
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Rhomboid Intercostal Block vs Erector Spinae Block
NCT070406181 location